Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Collagen and HA-based Biomaterials Market by Type (Urinary Incontinence, Corneal Shields, Facial Aesthetic Dermal Fillers, Viscosupplements  , Viscoelastics, Wound Dressings, Others) and by Application (Food, Medicine, Cosmetics, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A12334

Pages: NA

Charts: NA

Tables: NA

Collagen and HA-based Biomaterials Market Overview: 2030

Biomaterial refers to any matter, surface, or construct that interacts with biological systems. Biomaterials can be derived from nature or synthesized in the laboratory using metallic components, polymers, ceramics, or composite materials. Medical devices made of biomaterials are often used to replace or augment a natural function. Examples include heart valves, hip replacements, and materials used regularly in dentistry and surgery. Biomaterial plays an integral role in medicine today—restoring function and facilitating healing for people after injury or disease. Hyaluronic acid and collagen are two naturally occurring substances found in the human body. Each compound has a different purpose and benefit, and the main connection between them deals with the skin.

COVID-19 scenario analysis 

The consequences of lockdown and government-enforced restrictions as a result of the coronavirus pandemic have, of course, been felt heavily by businesses across all industries. Both the private healthcare sector and health and beauty businesses, which rely on close physical contact with their clients, have been significantly affected. Many small hospitals, dermatology clinics, and nursing homes, have been forced to shut their operations. Social distancing and localized curfews have resulted in delayed cosmetic surgical procedures. In addition, visa cancellations have led to a hiatus in medical tourism and can negatively impact the healthcare services market growth. The current outbreak of the COVID-19 pandemic has negatively impacted the collagen and HA-based biomaterials business.

Top impacting factors: market scenario analysis, trends, drivers, and impact analysis

Increase in focus on aesthetics is expected to surge the number of cosmetic procedures across the globe. Biomaterials are one of the most vital materials used in healthcare and pharmaceutical industries. Collagen and HA-based biomaterials are widely used in tissue engineering due to their wide availability, biodegradability, and biocompatibility. Collagen and HA-based biomaterials have potential application in the fields of regenerative medicine, food industry, personal healthcare, and development of prosthetics.

Rapid technological advancements, significant new product launches by industry players, surge in cosmetic procedures, and advantages offered by collagen & ha-based biomaterials are likely to fuel the growth of the global collagen and ha-based biomaterials market during the forecast period. According to the American Society of Plastic Surgeons (ASPS), almost 18 million people underwent surgical and minimally invasive cosmetic procedures in the U.S. in 2018. The three most popular procedures were botulinum toxin type A (Botox), soft tissue fillers, and chemical peels, which were up by 3%, 2%, and 1%, respectively, from 2017. Rise in prevalence of osteoporosis and osteoarthritis is further expected to drive the growth of this market over the next few years.

New product launches to flourish the market

New products that exhibit improved capabilities have been launched by leading market players. In May 2021, Orora launched products with the first bioidentical human collagen ingredient in North America. The products are formulated with geltor's bioactive human collagen ingredient, HumaColl21, a biodesigned peptide that works to stimulate the skin's natural collagen synthesis.

Key benefits of the report

  • This study presents the analytical depiction of the collagen and HA-based biomaterials industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the collagen and ha-based biomaterials market share.
  • The current market is quantitatively analyzed to highlight the collagen and ha-based biomaterials market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions answered in the collagen and ha-based biomaterials market research report

  • Which are the leading players active in the collagen and ha-based biomaterials market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What are the projections for the future that would help in taking further strategic steps?

Key Market Segments

  • By Type
    • Urinary Incontinence
    • Corneal Shields
    • Facial Aesthetic Dermal Fillers
    • Viscosupplements  
    • Viscoelastics
    • Wound Dressings
    • Others
  • By Application
    • Food
    • Medicine
    • Cosmetics
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA


Key Market Players

  • Collagen Solutions Plc
  • Abbott Laboratories
  • Allergan plc
  • Johnson and Johnson Services, Inc.
  • Galderma Laboratories L.P.
  • Bausch Health C ompanies Inc.
  • Anika Therapeutics, Inc.
  • BioCell Technology LLC
  • EternoGen
  • Sanofi
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: COLLAGEN AND HA-BASED BIOMATERIALS MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Urinary Incontinence

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Corneal Shields

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Facial Aesthetic Dermal Fillers

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Viscosupplements  

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Viscoelastics

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Wound Dressings

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

    • 4.8. Others

      • 4.8.1. Key Market Trends, Growth Factors and Opportunities

      • 4.8.2. Market Size and Forecast, By Region

      • 4.8.3. Market Share Analysis, By Country

  • CHAPTER 5: COLLAGEN AND HA-BASED BIOMATERIALS MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Food

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Medicine

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Cosmetics

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Others

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: COLLAGEN AND HA-BASED BIOMATERIALS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Type

      • 6.2.3. Market Size and Forecast, By Application

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Collagen And Ha-based Biomaterials Market

        • 6.2.5.1. Market Size and Forecast, By Type
        • 6.2.5.2. Market Size and Forecast, By Application
      • 6.2.6. Canada Collagen And Ha-based Biomaterials Market

        • 6.2.6.1. Market Size and Forecast, By Type
        • 6.2.6.2. Market Size and Forecast, By Application
      • 6.2.7. Mexico Collagen And Ha-based Biomaterials Market

        • 6.2.7.1. Market Size and Forecast, By Type
        • 6.2.7.2. Market Size and Forecast, By Application
    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Type

      • 6.3.3. Market Size and Forecast, By Application

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Collagen And Ha-based Biomaterials Market

        • 6.3.5.1. Market Size and Forecast, By Type
        • 6.3.5.2. Market Size and Forecast, By Application
      • 6.3.6. Germany Collagen And Ha-based Biomaterials Market

        • 6.3.6.1. Market Size and Forecast, By Type
        • 6.3.6.2. Market Size and Forecast, By Application
      • 6.3.7. Italy Collagen And Ha-based Biomaterials Market

        • 6.3.7.1. Market Size and Forecast, By Type
        • 6.3.7.2. Market Size and Forecast, By Application
      • 6.3.8. Spain Collagen And Ha-based Biomaterials Market

        • 6.3.8.1. Market Size and Forecast, By Type
        • 6.3.8.2. Market Size and Forecast, By Application
      • 6.3.9. UK Collagen And Ha-based Biomaterials Market

        • 6.3.9.1. Market Size and Forecast, By Type
        • 6.3.9.2. Market Size and Forecast, By Application
      • 6.3.10. Russia Collagen And Ha-based Biomaterials Market

        • 6.3.10.1. Market Size and Forecast, By Type
        • 6.3.10.2. Market Size and Forecast, By Application
      • 6.3.11. Rest Of Europe Collagen And Ha-based Biomaterials Market

        • 6.3.11.1. Market Size and Forecast, By Type
        • 6.3.11.2. Market Size and Forecast, By Application
    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Type

      • 6.4.3. Market Size and Forecast, By Application

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Collagen And Ha-based Biomaterials Market

        • 6.4.5.1. Market Size and Forecast, By Type
        • 6.4.5.2. Market Size and Forecast, By Application
      • 6.4.6. Japan Collagen And Ha-based Biomaterials Market

        • 6.4.6.1. Market Size and Forecast, By Type
        • 6.4.6.2. Market Size and Forecast, By Application
      • 6.4.7. India Collagen And Ha-based Biomaterials Market

        • 6.4.7.1. Market Size and Forecast, By Type
        • 6.4.7.2. Market Size and Forecast, By Application
      • 6.4.8. South Korea Collagen And Ha-based Biomaterials Market

        • 6.4.8.1. Market Size and Forecast, By Type
        • 6.4.8.2. Market Size and Forecast, By Application
      • 6.4.9. Australia Collagen And Ha-based Biomaterials Market

        • 6.4.9.1. Market Size and Forecast, By Type
        • 6.4.9.2. Market Size and Forecast, By Application
      • 6.4.10. Thailand Collagen And Ha-based Biomaterials Market

        • 6.4.10.1. Market Size and Forecast, By Type
        • 6.4.10.2. Market Size and Forecast, By Application
      • 6.4.11. Malaysia Collagen And Ha-based Biomaterials Market

        • 6.4.11.1. Market Size and Forecast, By Type
        • 6.4.11.2. Market Size and Forecast, By Application
      • 6.4.12. Indonesia Collagen And Ha-based Biomaterials Market

        • 6.4.12.1. Market Size and Forecast, By Type
        • 6.4.12.2. Market Size and Forecast, By Application
      • 6.4.13. Rest of Asia Pacific Collagen And Ha-based Biomaterials Market

        • 6.4.13.1. Market Size and Forecast, By Type
        • 6.4.13.2. Market Size and Forecast, By Application
    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Type

      • 6.5.3. Market Size and Forecast, By Application

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Collagen And Ha-based Biomaterials Market

        • 6.5.5.1. Market Size and Forecast, By Type
        • 6.5.5.2. Market Size and Forecast, By Application
      • 6.5.6. South Africa Collagen And Ha-based Biomaterials Market

        • 6.5.6.1. Market Size and Forecast, By Type
        • 6.5.6.2. Market Size and Forecast, By Application
      • 6.5.7. Saudi Arabia Collagen And Ha-based Biomaterials Market

        • 6.5.7.1. Market Size and Forecast, By Type
        • 6.5.7.2. Market Size and Forecast, By Application
      • 6.5.8. UAE Collagen And Ha-based Biomaterials Market

        • 6.5.8.1. Market Size and Forecast, By Type
        • 6.5.8.2. Market Size and Forecast, By Application
      • 6.5.9. Argentina Collagen And Ha-based Biomaterials Market

        • 6.5.9.1. Market Size and Forecast, By Type
        • 6.5.9.2. Market Size and Forecast, By Application
      • 6.5.10. Rest of LAMEA Collagen And Ha-based Biomaterials Market

        • 6.5.10.1. Market Size and Forecast, By Type
        • 6.5.10.2. Market Size and Forecast, By Application
  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Galderma Laboratories L.P.

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Allergan Plc

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Collagen Solutions Plc

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Anika Therapeutics, Inc.

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Johnson And Johnson Services, Inc.

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Sanofi

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Bausch Health C Ompanies Inc.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. BioCell Technology LLC

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Abbott Laboratories

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. EternoGen

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL COLLAGEN AND HA-BASED BIOMATERIALS MARKET, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR URINARY INCONTINENCE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR CORNEAL SHIELDS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR FACIAL AESTHETIC DERMAL FILLERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR VISCOSUPPLEMENTS  , BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR VISCOELASTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR WOUND DRESSINGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL COLLAGEN AND HA-BASED BIOMATERIALS MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR FOOD, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR MEDICINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR COSMETICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL COLLAGEN AND HA-BASED BIOMATERIALS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. NORTH AMERICA COLLAGEN AND HA-BASED BIOMATERIALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 18. U.S. COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 19. U.S. COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 20. CANADA COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 21. CANADA COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 22. MEXICO COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 23. MEXICO COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 24. EUROPE COLLAGEN AND HA-BASED BIOMATERIALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 25. EUROPE COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 26. EUROPE COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 27. FRANCE COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 28. FRANCE COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 29. GERMANY COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 30. GERMANY COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 31. ITALY COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 32. ITALY COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 33. SPAIN COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 34. SPAIN COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 35. UK COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 36. UK COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 37. RUSSIA COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 38. RUSSIA COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 39. REST OF EUROPE COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 40. REST OF EUROPE COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 41. ASIA-PACIFIC COLLAGEN AND HA-BASED BIOMATERIALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 42. ASIA-PACIFIC COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 43. ASIA-PACIFIC COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 44. CHINA COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 45. CHINA COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 46. JAPAN COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 47. JAPAN COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 48. INDIA COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 49. INDIA COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 50. SOUTH KOREA COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 51. SOUTH KOREA COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 52. AUSTRALIA COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 53. AUSTRALIA COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 54. THAILAND COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 55. THAILAND COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 56. MALAYSIA COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 57. MALAYSIA COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 58. INDONESIA COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 59. INDONESIA COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 60. REST OF ASIA PACIFIC COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 61. REST OF ASIA PACIFIC COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 62. LAMEA COLLAGEN AND HA-BASED BIOMATERIALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 63. LAMEA COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 64. LAMEA COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 65. BRAZIL COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 66. BRAZIL COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH AFRICA COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 68. SOUTH AFRICA COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 69. SAUDI ARABIA COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 70. SAUDI ARABIA COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 71. UAE COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 72. UAE COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 73. ARGENTINA COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 74. ARGENTINA COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 75. REST OF LAMEA COLLAGEN AND HA-BASED BIOMATERIALS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 76. REST OF LAMEA COLLAGEN AND HA-BASED BIOMATERIALS, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 77. GALDERMA LABORATORIES L.P.: KEY EXECUTIVES
  • TABLE 78. GALDERMA LABORATORIES L.P.: COMPANY SNAPSHOT
  • TABLE 79. GALDERMA LABORATORIES L.P.: OPERATING SEGMENTS
  • TABLE 80. GALDERMA LABORATORIES L.P.: PRODUCT PORTFOLIO
  • TABLE 81. GALDERMA LABORATORIES L.P.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 82. ALLERGAN PLC: KEY EXECUTIVES
  • TABLE 83. ALLERGAN PLC: COMPANY SNAPSHOT
  • TABLE 84. ALLERGAN PLC: OPERATING SEGMENTS
  • TABLE 85. ALLERGAN PLC: PRODUCT PORTFOLIO
  • TABLE 86. ALLERGAN PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 87. COLLAGEN SOLUTIONS PLC: KEY EXECUTIVES
  • TABLE 88. COLLAGEN SOLUTIONS PLC: COMPANY SNAPSHOT
  • TABLE 89. COLLAGEN SOLUTIONS PLC: OPERATING SEGMENTS
  • TABLE 90. COLLAGEN SOLUTIONS PLC: PRODUCT PORTFOLIO
  • TABLE 91. COLLAGEN SOLUTIONS PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 92. ANIKA THERAPEUTICS, INC.: KEY EXECUTIVES
  • TABLE 93. ANIKA THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 94. ANIKA THERAPEUTICS, INC.: OPERATING SEGMENTS
  • TABLE 95. ANIKA THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 96. ANIKA THERAPEUTICS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 97. JOHNSON AND JOHNSON SERVICES, INC.: KEY EXECUTIVES
  • TABLE 98. JOHNSON AND JOHNSON SERVICES, INC.: COMPANY SNAPSHOT
  • TABLE 99. JOHNSON AND JOHNSON SERVICES, INC.: OPERATING SEGMENTS
  • TABLE 100. JOHNSON AND JOHNSON SERVICES, INC.: PRODUCT PORTFOLIO
  • TABLE 101. JOHNSON AND JOHNSON SERVICES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 102. SANOFI: KEY EXECUTIVES
  • TABLE 103. SANOFI: COMPANY SNAPSHOT
  • TABLE 104. SANOFI: OPERATING SEGMENTS
  • TABLE 105. SANOFI: PRODUCT PORTFOLIO
  • TABLE 106. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 107. BAUSCH HEALTH C OMPANIES INC.: KEY EXECUTIVES
  • TABLE 108. BAUSCH HEALTH C OMPANIES INC.: COMPANY SNAPSHOT
  • TABLE 109. BAUSCH HEALTH C OMPANIES INC.: OPERATING SEGMENTS
  • TABLE 110. BAUSCH HEALTH C OMPANIES INC.: PRODUCT PORTFOLIO
  • TABLE 111. BAUSCH HEALTH C OMPANIES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. BIOCELL TECHNOLOGY LLC: KEY EXECUTIVES
  • TABLE 113. BIOCELL TECHNOLOGY LLC: COMPANY SNAPSHOT
  • TABLE 114. BIOCELL TECHNOLOGY LLC: OPERATING SEGMENTS
  • TABLE 115. BIOCELL TECHNOLOGY LLC: PRODUCT PORTFOLIO
  • TABLE 116. BIOCELL TECHNOLOGY LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 118. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 119. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 120. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 121. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. ETERNOGEN: KEY EXECUTIVES
  • TABLE 123. ETERNOGEN: COMPANY SNAPSHOT
  • TABLE 124. ETERNOGEN: OPERATING SEGMENTS
  • TABLE 125. ETERNOGEN: PRODUCT PORTFOLIO
  • TABLE 126. ETERNOGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL COLLAGEN AND HA-BASED BIOMATERIALS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL COLLAGEN AND HA-BASED BIOMATERIALS MARKET
  • FIGURE 3. SEGMENTATION COLLAGEN AND HA-BASED BIOMATERIALS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN COLLAGEN AND HA-BASED BIOMATERIALS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCOLLAGEN AND HA-BASED BIOMATERIALS MARKET
  • FIGURE 11. COLLAGEN AND HA-BASED BIOMATERIALS MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR URINARY INCONTINENCE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR CORNEAL SHIELDS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR FACIAL AESTHETIC DERMAL FILLERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR VISCOSUPPLEMENTS  , BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR VISCOELASTICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR WOUND DRESSINGS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. COLLAGEN AND HA-BASED BIOMATERIALS MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 20. COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR FOOD, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR MEDICINE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR COSMETICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. COLLAGEN AND HA-BASED BIOMATERIALS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 25. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 26. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 27. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 28. COMPETITIVE DASHBOARD
  • FIGURE 29. COMPETITIVE HEATMAP: COLLAGEN AND HA-BASED BIOMATERIALS MARKET
  • FIGURE 30. TOP PLAYER POSITIONING, 2024
  • FIGURE 31. GALDERMA LABORATORIES L.P.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. GALDERMA LABORATORIES L.P.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. GALDERMA LABORATORIES L.P.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. ALLERGAN PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. ALLERGAN PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. ALLERGAN PLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. COLLAGEN SOLUTIONS PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. COLLAGEN SOLUTIONS PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. COLLAGEN SOLUTIONS PLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. ANIKA THERAPEUTICS, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. ANIKA THERAPEUTICS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. ANIKA THERAPEUTICS, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. JOHNSON AND JOHNSON SERVICES, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. JOHNSON AND JOHNSON SERVICES, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. JOHNSON AND JOHNSON SERVICES, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. SANOFI: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. SANOFI: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. SANOFI: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. BAUSCH HEALTH C OMPANIES INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. BAUSCH HEALTH C OMPANIES INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. BAUSCH HEALTH C OMPANIES INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. BIOCELL TECHNOLOGY LLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. BIOCELL TECHNOLOGY LLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. BIOCELL TECHNOLOGY LLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 55. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 56. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 57. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 58. ETERNOGEN: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 59. ETERNOGEN: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 60. ETERNOGEN: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Collagen and HA-based Biomaterials Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue